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The transfer of maternal immune factors to the newborn is critical for protection from 
infectious disease in early life. Maternally acquired passive immunity provides protec-
tion until the infant is beyond early life’s increased susceptibility to severe infections 
or until active immunity is achieved following infant’s primary immunization. However, 
as reviewed here, human immunodeficiency virus (HIV) infection alters the transfer of 
immune factors from HIV-infected mothers to the HIV-exposed newborns and young 
infants. This may relate to the immune activation in HIV-infected pregnant women, 
associated with the production of inflammatory cytokines at the maternofetal interface 
associated with inflammatory responses in the newborn. We also summarize mother-tar-
geting interventions to improve the health of infants born to HIV-infected women, such 
as immunization during pregnancy and reduction of maternal inflammation. Maternal 
immunization offers the potential to compensate for the decreased transplacentally 
transferred maternal antibodies observed in HIV-exposed infants. Current data suggest 
reduced immunogenicity of vaccines in HIV-infected pregnant women, possibly reducing 
the protective impact of maternal immunization for HIV-exposed infants. Fortunately, 
levels of antibodies appear preserved in the breast milk of HIV-infected women, which 
supports the recommendation to breast-feed during antiretroviral treatment to protect 
HIV-exposed infants.
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iNTRODUCTiON
Young infants are vulnerable to severe morbidity and mortality caused by infectious diseases. Every 
year, more than 1 million children worldwide die from infections during the first 28 days of life (1, 2). 
This susceptibility to infectious pathogens involves multiple factors, including lack of immunological 
memory in the newborn infant and the regulatory responses required to adapt the immune system to 
the transition from a relatively sterile to a microbe-rich environment (3, 4). The transfer of maternal 
immune factors, through the placenta and breast milk, to the fetus and young infant plays a critical 
role in augmenting defense against infectious pathogens and participates in the establishment of 
immune homeostasis in early life. Specifically, maternal antibodies are actively transferred to the 
fetus in utero and provide protection against pathogens that are prevalent in the community (5), 
and breast-feeding extends the time for transfer of maternal immune factors, providing important 
TABLe 1 | Transplacental transfer of pathogen- and vaccine-specific antibodies from Hiv-infected pregnant women to the newborn.
Settings Main results
Transfer of antibacterial antibodies
Streptococcus pneumonia (Spn)
Brazil,  
1989–1992
Transplacental transfer of total anti-PCP IgG was reduced in newborns of HIV-infected (n = 46) as compared with HIV-uninfected  
mothers (n = 53)a (27)
Malawi,  
1993–1994
Maternal HIV infection was not associated with reduced placental transfer or lower cord total anti-PCP IgGa (35)
South Africa,  
2009–2010
At birth, HEU newborns (n = 46) had significantly lower total anti-PCP IgG levels than HU newborns (n = 54) (31)
United Kingdom, 
2011–2012
Transplacental transfer of total anti-PCP IgG was reduced by 28% in HEU (n = 12) as compared with HU newborns (n = 96). HEU infants (n = 13) 
had lower levels of total anti-PCP IgG compared with HU (34)
India, 2002–2007; 
Bangladesh,  
2004–2005
HIV-exposed infants (n = 74, India) compared with HU (n = 98, Bangladesh) had lower umbilical cord GMTs for serotype-specific Spn antibodiesb 
and lower geometric mean ratio of cord: maternal antibody concentrations for all serotypesb except serotype 6B. The proportion of umbilical cord 
samples with Spn IgG ≥ 0.35 μg/ml, was lower in HIV-exposed infants than HU for all serotypesb (33)
Haemophilus influenzae type b (Hib)
South Africa,  
2009–2010
At birth, HEU infants (n = 46) had significantly lower levels of anti-Hib IgG than HU infants (n = 54). There was lower proportion of HEU infants with 
levels considered to be protective against Hib (anti-Hib IgG titers > 1 mg/l) as compared with HU infants (31)
Uganda,  
2010–2013 
Transplacental transfer of anti-Hib IgG in HIV-infected mothers was 43%. Ninety percent of the infants had anti-Hib IgG levels above the threshold 
for long-term protection (>1.0 μg/ml) (38)
United Kingdom, 
2011–2012
The transplacental transfer of anti-Hib IgG was reduced by 61%% in HEU (n = 12) as compared with HU infants (n = 96) (34)
(Continued)
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protection against infectious disease morbidity and mortality in 
infancy (6, 7).
Chronic maternal infections can alter the immune factors that 
are transferred to the young infant, and thereby modulate their 
susceptibility to homologous or heterologous infectious pathogens 
(8). Human immunodeficiency virus (HIV) infection is known to 
have a profound impact on B lymphocyte and antibody responses 
to pathogens and vaccines (9, 10). These alterations are linked 
to immune activation and are improved by antiretroviral (ARV) 
therapy (10–12). Studies suggested that both HIV infection and 
pregnancy promote the activation of the immune system (13), 
and HIV infection alters the transfer of maternal immune factors 
to the newborn and young infant. As reviewed elsewhere in this 
research topic, clinical and epidemiological studies have shown 
that infants born to HIV-infected women, but not infected by 
HIV, are at increased risk of severe infections, particularly during 
the first year of life (14). Although the mechanisms underlying this 
increased susceptibility have not yet been identified, alterations 
in the transfer of maternal immune factors could play a central 
role. As severe infections observed in HIV-exposed uninfected 
(HEU) infants involve multiple pathogens, including bacteria, 
viruses, and parasites, the immune factors involved should have 
the potential to impact defenses against a broad spectrum of 
microbes (15–18).
The aim of this article is to review the current knowledge on 
the transfer of immune factors from HIV-infected mothers to 
HEU infants through the placenta and breast milk and to discuss 
maternal interventions that could improve the health of these 
children. The transfer of HIV-specific immunity is not discussed 
in this review. As the definition of HEU requires follow-up of 
HIV-exposed infants to confirm the absence of transmission, 
this term will only be used when HIV-exposed infants were 
confirmed uninfected. Whenever these data are not available 
from the referred studies the term “HIV-exposed infant” will 
be used.
iMPACT OF MATeRNAL Hiv iNFeCTiON 
ON THe TRANSPLACeNTAL TRANSFeR 
OF ANTiBODieS
Immunoglobulin G (IgGs) are specifically transported from 
maternal to fetal blood via the neonatal Fc receptor (FcRn) 
expressed in placental syncytiotrophoblasts (19). Most of this 
transfer occurs during the third trimester of pregnancy (19, 20). 
The efficiency of IgG transfer (measured as the ratios between 
cord blood and maternal blood antibody levels) differs between 
antibodies targeting different antigens or pathogens and ranges 
from up to 200% for pertussis and 70% for Group B Streptococcus 
(GBS) (21–23). Although direct evidence for this is limited, this 
antigen-specific variability is, at least partly, related to differences 
in the efficiency of the transfer of IgG subclasses. The highest 
transfer is observed for IgG1 that is predominantly induced by 
protein antigens (e.g., pertussis), whereas the lowest transfer is 
observed for IgG2 that is predominantly induced by polysaccha-
ride antigens (e.g., GBS capsular antigen) (24–26). In early 1990s, 
studies of Brazilian women indicated that although HIV-infected 
women had higher total IgG levels than HIV-uninfected mothers 
at delivery, the transplacental transfer of total as well as antigen-
specific IgG to HIV-exposed newborns was reduced (27,  28). 
These early studies were confirmed by many other investigators 
and extended to a number of pathogen and vaccine antigens 
(Table 1). To date, the mechanism underlying this reduced trans-
fer remains poorly understood. The inverse association observed 
Settings Main results
Group B Streptococcus (GBS)
South Africa, 
2009–2011
HIV infection was associated with a reduction in placental transfer of anti-GBS antibodies to serotypes II and V. HEU infants (n = 45) had lower 
antibody GMTs to GBS capsular serotypes (Ia, Ib, II, III, and V) than HU infants (n = 54). Antibody GMTs to all serotypes remained lower at 16 weeks 
of age in HEU as compared with HU infants (39)
South Africa, 2013 Antibodies against GBS capsular serotypes (Ia, Ib, III, and V) and the cord-maternal ratio (serotypes Ia and III) were lower in HEU (n = 83) than in HU 
(n = 81) newborns. The cord blood median surface-protein antibody concentrations were lower in HEU compared with HU newborns for selected 
GBS surface proteins (40)
Tetanus (TT)
Brazil, 1989–1992 Transplacental transfer of anti-TT IgG was reduced in sera of newborns of HIV-infected (n = 46) as compared with -uninfected mothers (n = 53)a (28)
Malawi, 
1993–1994
Maternal HIV infection was not associated with lower cord anti-TT IgG or reduced placental transfer of anti-TT IgGa (35)
Kenya, 
1996–1997
There was a 52% reduction in anti-TT IgG concentrations in newborns born to HIV-infected (n = 87) as compared with -uninfected (n = 617) 
women. Increased risk for seronegativity (anti-TT IgG < 0.1 IU/ml) in newborns of women infected with HIV compared with -uninfected women (29)
South Africa, 
2009–2010
Tranplacental transfer of anti-TT IgG was reduced in HIV-infected (n = 46) as compared with -uninfected women (n = 54). HEU infants had lower 
anti-TT IgG at birth as compared with HU infants. There was significant lower proportion of HEU infants with sero-protective levels against tetanus 
(anti-TT IgG > 0.1 IU/ml) (31)
United Kingdom, 
2011–2012
Anti-TT IgG levels were similar between HEU and HU infants at birth (34)
Nigeria, date not 
provided
HIV-exposed newborns (n = 10) were more likely to have cord:maternal transfer ratio of anti-TT IgG < 1 than HU newborns (n = 152).  
HIV-exposed newborns were more likely to be seronegative (anti-TT IgG < 0.1 IU/ml) than HU newborns (43)
Pertussis
South Africa, 
2009–2010
Transplacental transfer of pertussis antibodies was reduced in HIV-infected women (n = 46) as compared with -uninfected women (n = 54).  
HEU newborns had lower levels of pertussis-specific antibodies compared with HU infants (31)
United Kingdom, 
2011–2012
Transplacental transfer of collective IgG response to pertussis antigens (PT and FHA) was reduced by 32% in HEU (n = 12) as compared with HU 
newborns (n = 96). Pertussis-specific antibody levels were similar in HEU and HU newborns (34)
Transfer of antiviral antibodies
Measles
Brazil,  
1989–1990
No difference in anti-measles IgG titers between newborns of HIV-infected (n = 16) and -uninfected (n = 18) pregnant women. The number of 
newborns with protective anti-measles antibodies was lower among newborns of HIV-infected of -uninfected mothersa (27)
Brazil,  
1989–1992
Transplacental transfer of anti-measles IgG was reduced in sera of newborns of HIV-infected (n = 46) as compared with -uninfected mothers 
(n = 53)a (28)
Malawi, 
1993–1994
Maternal HIV infection was not associated with lower cord anti-measles antibodies or reduced transplacental transfer of anti-measles  
antibodiesa (35)
Kenya, 
1996–1997
Maternal HIV infection was associated with 15.5% reduction in the transfer of anti-measles antibodies to HEU (n = 91) as compared with HU 
newborns. HEU newborns had a 35% reduction in measles antibody levels and a fourfold increased risk of being seronegative than HU newborns (46)
Polio
Brazil,  
1989–1990
Anti-poliovirus 1 and 2 titers in umbilical cord sera were lower in newborns of HIV-infected (n = 16) than -uninfected women (n = 18)
A reduction in transplacental transfer of type 2 poliovirus antibodies was demonstrated in newborns of women infected with HIV than -uninfected 
womena (27)
varicella zoster virus (vZv)
Brazil, 1989–1992 Transplacental transfer of anti-VZV IgG was reduced in newborns of HIV-infected (n = 46) as compared with -uninfected womena (n = 53) (28)
Transfer of antimalarial antibodies
Kenya, 1997 Maternal HIV infection was associated with reduced transfer and reduced newborn levels of antibodies to the (NANP) 5 antigen but not of other 
malaria antigensa (42)
Kenya, 
1996–2000
Reduced levels of antibodies against CSP, liver-stage antigen 1, and RAP1 at birth in newborns of HIV-infected women (n = 254) (43)
Mozambique, 
2003–2006
Maternal HIV infection was associated with decreased levels of cord IgG1 and IgG3 against MSP1 and lysate, with cord IgG1 against apical 
membrane antigen 1 (AMA1), and with cord IgG3 against EBA175. Maternal HIV infection was associated with reduced transfer of IgG1 against 
AMA1, of IgG1 and IgG3 against lysate, and of IgG3 against MSP1 and EBA175 (48)
HIV, human immunodeficiency virus; PCP, pneumococcal capsular polysaccharide; IgG, immunoglobulin G; HEU, HIV-exposed uninfected; HU, HIV-unexposed; GMT, geometric 
mean titers; Hib, Hemophilus influenzae B; GBS, group B Streptococcus; CSP, circumsporozoite protein; RAP, rhoptry associated protein; MSP, merozoite surface protein; AMA, 
apical membrane antigen; EBA, erythrocyte-binding antigen.
aInfants were not followed with HIV testing.
bSerotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F, and 23F.
TABLe 1 | Continued
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between maternal hypergammaglobulinemia and IgG transfer 
ratios has been interpreted as evidence that maternal IgG may 
saturate the placental FcRn (28–30). As our understanding of the 
mechanisms underlying transplacental transfer of IgG remains 
very poor, this model remains speculative.
Transfer of Antibacterial Antibodies
Streptococcus pneumoniae
Studies consistently showed that maternal HIV infection is associ-
ated with a decrease in the transfer of antibodies to Streptococcus 
pneumoniae. In South Africa, HIV-infected mothers had lower 
titers of total pneumococcal capsular polysaccharide (PCP) 
antibodies and a 15% reduction in antibody transfer ratios as 
compared with HIV-negative mothers; this resulted in lower PCP 
antibody titers in their newborns (31). In Malawi, the transfer 
of PCP antibodies was inversely correlated with HIV viral load 
and correlated with CD4 counts in ARV therapy-naive pregnant 
women (32). In South Asia, HIV-infected mothers had lower 
titers of antibodies to multiple PCP serotypes (1, 4, 5, 9V, 14, 
18C, 19F, and 23F) and a 23–48% reduction in antibody transfer 
ratios as compared with HIV-negative mothers (33). In United 
Kingdom (UK), HIV-infected mothers had similar levels of anti-
PCP antibodies compared with HIV-negative mothers but had 
a 28% reduction in antibody transfer ratios; this again resulted 
in lower antibody titers in their newborns (34). In these studies, 
most pregnant women had not received pneumococcal vaccines, 
i.e., measured antibodies were induced by natural exposure to 
S. pneumoniae. However, while the transfer of naturally occurring 
(i.e., infection-induced) PCP IgG was reduced by about 20% in 
HIV-infected mothers (28, 35), antibody transfer ratios following 
immunization of pregnant women in Brazil with a pneumococcal 
polysaccharide vaccine was also reduced to only 46–72% as com-
pared with unexposed newborns (36). Thus, infection-induced 
as well as vaccine-induced anti-PCP IgG transfer to her newborn 
is reduced in HIV-infected women. The clinical relevance of 
reduced PCP antibody transfer to HIV-exposed infants has not 
been clearly established. In Malawi, respiratory tract infections 
were more common among children with lower PCP antibodies, 
but no difference in mortality was observed (32, 37). A study in 
Belgium showed that HEU children are at high risk of invasive 
pneumococcal infections, but the association with the level of 
maternal antibodies was not assessed (16).
Haemophilus influenzae Type b
Maternal HIV infection is also associated with a reduced 
transplacental transfer of Haemophilus influenzae type b (Hib) 
antibodies. In South Africa, transfer of Hib antibodies to HEU 
newborns was reduced by 23% as compared with HIV-unexposed 
newborns, and this was associated with 35% reduction in the 
proportion of newborns with protective antibody levels (anti-Hib 
IgG > 1 mg/l) (31). In Uganda, 43% of maternal Hib antibodies 
were transplacentally transferred to HEU newborns; however, 
90% of HEU newborns had protective antibody levels (38). 
Interestingly, these antibodies were mostly of IgG1 subclass, an 
unexpected finding given the polysaccharide nature of the Hib 
antigen. In UK, maternal HIV infection was associated with a 
61% reduction in the transfer of Hib antibodies, but antibody 
levels were not significantly different in HEU and HIV-unexposed 
newborns (34). In these studies, antibodies were induced by 
natural infection. No data are available regarding the transfer of 
Hib vaccine-induced antibodies. Also, the clinical impact of the 
decreased antibody transfer has not been established.
Group B Streptococcus
Data indicating that HEU infants are at high risk of invasive 
GBS infections stimulated studies that focused on the impact of 
maternal HIV in the transfer of anti-GBS immunity (15). In South 
Africa, maternal HIV infection was associated with lower levels 
of antibodies to GBS capsular polysaccharide antigens (serotypes 
Ia, Ib, II, III, and V) and a 58 and 32% reduction in transfer ratios 
of antibodies to serotypes II and V, respectively (39). These results 
were confirmed in another study from South Africa, which also 
demonstrated reduced levels of antibodies to GBS capsular 
polysaccharide antigens and surface proteins in HIV-infected 
mothers and their newborns (40). However, the transfer ratios 
of antibodies to GBS proteins were not different in HIV-infected 
and -uninfected mothers. No association was observed between 
maternal antibody levels or transfer ratios and CD4 counts or 
viral load (40). A more recent study also conducted in South 
Africa demonstrated that maternal HIV infection reduces anti-
body response to a GBS glycoconjugate vaccine, but does not 
impact the transfer ratios of vaccine-induced antibodies to the 
HIV-exposed newborns (41).
Tetanus
The impact of maternal HIV infection on the transplacental 
transfer of tetanus toxoid (TT) antibodies varies between studies 
and populations. Early studies in Brazil indicated reduced trans-
fer of TT antibodies in HIV-infected mothers, but this was not 
confirmed in a study in Malawi (28, 35). In Kenya, TT antibody 
titers were 38% lower in HIV-infected than in -uninfected women 
at delivery and 52% lower in HIV-exposed as compared with 
HIV-unexposed newborns (29). Similar results were obtained in 
a second, but not in a third, study in Kenya (42, 43). The reasons 
for these discrepant results are not clear but could involve inter-
actions with other pathogens coinfecting pregnant women and 
affecting transplacental transfer of maternal antibodies, including 
malaria (43). In South Africa, a 27% reduction of TT antibody 
transfer ratios was observed in HIV-infected as compared with 
-uninfected women, and this resulted in a 30% reduction in sero-
protection rates in HEU as compared with HIV-unexposed new-
borns (31). In UK, maternal HIV infection was associated with a 
32% reduction in transfer of TT antibodies, but antibody levels 
were not significantly different in HEU and HIV-unexposed new-
borns (34). Recent data from Nigeria showed that HIV-exposed 
newborns were nearly 34 times more likely than HIV-unexposed 
newborns to have seronegative TT titers in cord blood (anti-TT 
IgG < 0.1 IU/ml) (44). Although this has not been determined, 
these data suggest that HEU newborns may be at higher risk of 
tetanus than children born to HIV-negative women (45).
Pertussis
Maternal HIV infection is associated with reduced transplacental 
transfer of pertussis antibodies, but the resulting antibody levels 
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in HEU newborns differ between populations. In South Africa, 
HIV-infected mothers had a 40% reduction in pertussis antibody 
transfer ratios, and this resulted in lower levels of pertussis 
antibodies in HEU as compared with unexposed newborns (31). 
A  marked reduction in the transplacental transfer of pertussis 
antibodies was also observed in UK, but no significant differ-
ence in antibody levels was observed between HEU and HIV-
unexposed newborns (34). The clinical implications of these 
observations have not been established.
Transfer of Antiviral Antibodies
Measles Virus
In Brazil, HEU newborns had 20% lower measles antibody levels 
than HIV-unexposed newborns (28). In Kenya, maternal HIV 
infection was associated with a 16% reduction in the transfer 
ratios of measles antibodies; HEU newborns had a 35% reduction 
in measles antibody levels and a fourfold increase in the rate of 
measles seronegativity (46). In contrast, HIV-infected pregnant 
women in Malawi had higher measles antibody levels than -unin-
fected mothers and their newborns had similar antibody levels 
than unexposed newborns (35). In another study, in Kenya, high 
maternal HIV viral load was correlated with decreased transfer 
ratios of measles antibodies (47).
Polio and Varicella Zoster Viruses
Limited data are available regarding the transfer of polio or 
varicella zoster virus (VZV) antibodies in HIV-infected mothers. 
In Brazil, HEU newborns had lower levels of polio antibodies 
than HIV-unexposed newborns and decreased transfer ratios 
were demonstrated for polio virus 2 (27). Higher levels of VZV 
antibodies were detected in HIV-infected pregnant women as 
compared with -uninfected controls (28). But, while transpla-
cental transfer of VZV antibodies was reduced by maternal HIV 
infection, similar antibody levels were detected in HEU and 
unexposed newborns (28).
Transfer of Antimalarial Antibodies
Limited data are available regarding the transplacental transfer 
of maternal antibodies directed against parasite antigens. 
A study in Kenya analyzed the transfer of antibodies to a series 
of Plasmodium falciparum antigens. Transfer ratios were about 
100% for all tested antigens, and maternal HIV infection was 
associated with a reduction in transfer of only one antigen, the 
circumsporozoite protein (NANP) 5 (42). In another study, in 
Kenya, HIV-exposed newborns had lower levels of antibodies 
to several pre-erythrocytic and erythrocytic-stage antigens as 
compared with HIV-unexposed newborns (43). In Mozambique, 
maternal HIV infection was associated with reduced transfer 
rates of IgG1 and IgG3 to parasite lysate and erythrocytic-stage 
antigens (48).
impact of Maternal Hiv infection on the 
Quality of Transferred Antibodies
Whether maternal HIV infection alters the quality of antibod-
ies transferred to the newborn remains largely unexplored. 
In South Africa, reduced antibody-mediated complement 
C3b/iC3b deposition on GBS serotypes was detected in HIV-
infected as compared with HIV-uninfected mothers and HEU 
as compared with HIV-unexposed newborns (39). However, 
the intrinsic complement deposition activity of the transferred 
antibodies was not assessed in this study. In a small study, 
Farouk et  al. observed reduced measles neutralizing activity 
of antibodies from HIV-exposed as compared with unexposed 
newborns, suggesting the intriguing possibility that maternal 
HIV infection alters the quality of antibodies transferred to 
their newborns (49).
TRANSFeR OF iNFLAMMATORY 
MeDiATORS FROM Hiv-iNFeCTeD 
PReGNANT wOMeN TO THe FeTUS
The production of inflammatory mediators induced by HIV infec-
tion may alter the immune homeostasis of healthy pregnancy, 
and this may have important consequences on the outcome of 
the pregnancy itself and on the health of HEU children. Maternal 
HIV infection is associated with an increased risk of preterm 
birth, a complication likely related to inflammation at the mater-
nofetal interface (50, 51). Inflammation in the fetus may result in 
fetal inflammatory response syndrome, but the incidence of this 
syndrome in HIV-exposed fetuses has not been reported (52, 53). 
Fetal inflammation may also alter the neurological development 
of HEU children and may participate in their increased suscepti-
bility to severe infections (54–57).
inflammatory Responses in Hiv-infected 
Pregnant women
Studies performed in the 1990s indicated increased serum 
levels of several inflammatory mediators, including tumor 
necrosis factor (TNF)-α, neopterin, and β2 microglobulin, in 
HIV-infected as compared with -uninfected pregnant women, 
and these levels increased from the first to the third trimester 
of pregnancy (58). These observations were confirmed by later 
studies indicating that HIV-infected pregnant women have 
increased levels of inflammatory mediators in the plasma and 
in cervicovaginal fluid as compared with -uninfected pregnant 
women and to HIV-infected non-pregnant women, indicat-
ing that both HIV infection and pregnancy contribute to the 
production of inflammatory mediators (59). Studies suggest 
that peripheral blood cells may contribute to the production 
of inflammatory mediators in HIV-infected pregnant women 
(60). Whether these mediators could cross the placenta and 
reach the fetal circulation has not been established. Ex vivo 
placental perfusion models suggested that some cytokines could 
be transferred, but these observations have not been reproduced 
in other studies (61, 62). No study has examined the transfer 
of cytokines through the placenta of HIV-infected women. A 
recent study suggested that maternal HIV infection is associated 
with increased serum levels of inflammatory markers related to 
microbial translocation [lipopolysaccharide (LPS) modulators 
soluble CD14 and LPS-binding protein] and that these markers 
were associated with preterm delivery (51); however, the cord 
blood levels of these pro-inflammatory mediators were not 
TABLe 2 | Mother-targeted interventions to optimize Hiv-exposed infants’ 
health.
 1. immunization of Hiv-infected pregnant women during pregnancy
 – immunization of Hiv-infected pregnant women with influenza 
vaccine: immunization with two doses of pandemic H1N1 monovalent 
vaccine induced similar seroprotection rates in HIV-infected pregnant 
women and their newborns at delivery. Seroprotection in HIV-exposed 
infants waned rapidly (76). Immunization with trivalent inactivated 
influenza vaccine (A/California/7/2009, A/Victoria/210/2009, and B/
Brisbane/60/2008) induced lower seroprotection rates in HIV-infected 
as compared with -uninfected pregnant women, but similar vaccine 
efficacy (78). Lower maternal antibody transfer ratios were observed in 
immunized HIV-infected as compared with -uninfected women for the 
California and not for the two other vaccine strains (79)
 – immunization of Hiv-infected pregnant women with 
pneumococcal vaccine: immunization of pregnant women with a 
pneumococcal polysaccharide vaccine during the third trimester of 
pregnancy was associated with 46–72% antibody transfer ratios (36). 
Serotype-specific antibody levels waned rapidly in the HIV-exposed 
infants over the first 6 months of life with the estimated time to antibody 
levels <0.35 μg/ml for different serotypes (1, 3, 5, 6B, and 9V) ranging 
between 0.6 and 2.7 months (36)
 – immunization of Hiv-infected pregnant women with GBS 
vaccine: immunization with non-adjuvanted GBS capsular 
polysaccharide during pregnancy induced lower antibody response 
in HIV-infected than in -uninfected women (41). Transfer ratios were 
similar but antibody levels were lower in HIV-exposed as compared with 
unexposed newborns (41)
 2. Reduction of maternal inflammation
 – Placental tissues from HIV-infected pregnant women on combined 
ARV treatment expressed lower levels of mRNA for TNF-α and IL-8 as 
compared with -uninfected women (82).
HIV, human immunodeficiency virus; GBS, group B Streptococcus; ARV, antiretroviral; 
TNF-α, tumor necrosis factor; IL, interleukin.
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different among newborns of HIV-infected and -uninfected 
women, and the ratio of transfer across the placenta was not 
provided.
Placental inflammation
Several studies suggest that HIV infection promotes inflamma-
tory responses at the level of the placenta. Placental immune cells 
from HIV-infected women secrete higher levels of inflammatory 
cytokines, including interleukin (IL)-1β and IL-6, as compared 
with HIV-uninfected women (63). In one study, maternal HIV 
infection was associated with an increased production of inflam-
matory cytokines, including IL-1β, IL-6, and TNF-α, by placental 
trophoblasts (epithelial cells of fetal origin) (64). In another study, 
HIV-infection was associated with an increased production of 
interferon (IFN)-β by trophoblasts but with similar production 
of IFN-α, IFN-γ, and chemokines as compared with -uninfected 
pregnancies (65). These results suggest that specific inflamma-
tory pathways may be activated at the placental level during HIV 
infection.
inflammation in Hiv-exposed Newborns
A restricted number of studies suggested that HIV-exposed 
newborns have signs of systemic inflammation. In South Africa, 
HIV-exposed newborns had increased serum levels of neopterin, 
suggesting myeloid cell activation (66). Interestingly, neopterin 
levels where higher in newborns of mothers who received nevi-
rapine prophylaxis. In Netherlands, increased levels of IL-1β and 
IL-8 were detected in the plasma of HIV-exposed as compared 
with unexposed newborns (67). Evidence for innate immune cell 
activation was provided by a study conducted in South Africa 
where peripheral blood innate immune cells of HEU infants 
mounted an enhanced inflammatory response to microbial 
products as compared with HIV-unexposed infants (68). In the 
USA, HEU newborns also displayed higher expression of T-cell 
costimulatory molecules by dendritic cells following LPS stimu-
lation as compared with unexposed newborns (69). In contrast, 
IL-12 responses were lower in HEU newborns, suggesting a 
potential impact on the quality of T-cell responses (70). Altered 
cytokine responses to lectin stimulation were also observed in 
Brazil (60). So, although a clear picture of the pathways involved 
and of the underlying mechanisms is not yet available, evidence 
indicates that peripheral blood cells of HEU newborns are phe-
notypically and functionally altered.
TRANSFeR OF MATeRNAL iMMUNe 
FACTORS BY BReAST-FeeDiNG
Breast milk contains antibodies and leukocytes that can partici-
pate in pathogen-specific immunity after birth. If the presence of 
HIV-specific antibodies in breast milk has been well studied, 
the impact of maternal HIV infection on the concentration of 
antibodies to other pathogens or vaccine antigens has been less 
well characterized (71–74). In Botswana, HIV-infected women 
had higher concentrations of total IgG, IgM, and IgA in breast 
milk as compared with -uninfected women; the levels in breast 
milk paralleled their hypergammaglobulinemia (75). However, 
different antigen specificities appeared to be differently affected, 
with IgG to H. influenzae detected at higher concentrations and 
IgG to Campylobacter jejuni, Helicobacter pylori, or S. pneumoniae 
detected at similar concentrations in breast milk of HIV-infected 
as compared with -uninfected women (75). These higher or 
preserved IgG concentrations in breast milk may compensate for 
the decreased transfer of maternal IgG through the placenta.
Very little data exist on the effect of maternal HIV infection 
on the cell-mediated and innate immunity in the breast milk; 
discussion of this is beyond the scope of this review.
MATeRNAL iNTeRveNTiONS TO 
PROMOTe iMMUNiTY iN HeU iNFANTS
Interventions in HIV-infected mothers have been identified that 
have the potential to promote immunity in HEU infants. They 
include maternal immunization and reduction of maternal inflam-
mation by ARV therapy (Table 2). The discussion about breast-
feeding during ARV therapy is beyond the scope of this review.
immunization of Hiv-infected  
Pregnant women
Immunization of HIV-infected pregnant women offers the poten-
tial to compensate for the reduced transfer of maternal antibodies 
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to HEU newborns. Yet, maternal immune responses may be 
affected both quantitatively and qualitatively by HIV infection. 
As a result, the benefit of this strategy has to be evaluated for 
each individual vaccine and vaccination strategy. The relatively 
few studies conducted on this topic have examined the response 
to influenza, tetanus, S. pneumoniae, and GBS vaccines.
Influenza
Immunization of pregnant women may protect the infant against 
influenza by reducing mother’s risk of influenza disease and by 
augmenting the transplacental transfer of influenza specific anti-
bodies to the infant. Current evidence indicates reduced immu-
nogenicity of inactivated influenza vaccines in HIV-infected as 
compared with -uninfected pregnant women and relatively rapid 
waning of maternal antibodies in HIV-exposed infants.
During the 2009 influenza season in the US, HIV-infected 
pregnant women on highly active ARV therapy (HAART) prior 
to or at study entry were immunized with two doses of pandemic 
H1N1 monovalent vaccine between 13 and 34 weeks of gestation 
(76). Antibody responses were lower than in HIV-uninfected 
historical controls. Seroprotection [hemagglutinin inhibition 
(HAI) titers ≥ 40] rates were similar in women and newborns at 
delivery (67 and 65%, respectively), indicating efficient transfer 
of maternal antibodies. However, maternal antibodies declined 
relatively rapidly in HIV-exposed infants, with seroprotection 
rates reaching only 26% in HIV-exposed infants at 3  months 
of age. A follow-up publication indicated a positive correlation 
between CD4 counts and antibody response to the first vaccine 
dose and minimal response to the second dose of vaccine (77).
In South Africa, a randomized placebo controlled trial meas-
ured the immunogenicity and efficacy of a trivalent inactivated 
influenza vaccine (A/California/7/2009, A/Victoria/210/2009, 
and B/Brisbane/60/2008) in HIV-infected and -uninfected preg-
nant women (78). Seroprotection rates (HAI titers) were lower 
in HIV-infected (43, 36, and 40% to California, Victoria, and 
Brisbane strains) as compared with HIV-uninfected pregnant 
women (73, 65, and 92% to California, Victoria, and Brisbane 
strains). However, vaccine efficacy was similar in both groups (57 
and 50% in HIV-infected and -uninfected women, respectively). 
Transfer ratios ranged between 0.7 and 1.0 in HIV-uninfected 
and between 0.7 and 1.4 in HIV-infected immunized women, 
suggesting no negative impact of maternal HIV infection on 
antibody transfer. The transfer ratios of antibodies were higher 
in the placebo as compared with the vaccinated group for the 
Victoria strain in HIV-uninfected women and for California and 
Victoria strains in HIV-infected women. At birth, seroprotec-
tion rates were 81, 60, and 82% in children born to immunized 
uninfected women and 61, 43, and 79% (California, Victoria, and 
Brisbane strains, respectively) in children born to immunized 
HIV-infected women. A follow-up publication included formal 
comparisons of maternal antibody transfer ratios and indicated 
lower ratios in immunized HIV-infected as compared with 
-uninfected women for the California and not for the two other 
vaccine strains (79). Intriguingly, maternal antibodies declined 
more rapidly in HIV-unexposed as compared with HIV-exposed 
children, with an estimated mean antibody half-life ranging from 
43 to 45 and 56 to 65 days, respectively (79).
Study of a relatively small cohort showed a lower immu-
nogenicity of a trivalent influenza vaccine in HIV-infected as 
compared with -uninfected pregnant women and a negative 
correlation with the frequency of regulatory T-cells in the HIV-
infected group (80).
Tetanus
Although maternal immunization with TT vaccine is the cor-
nerstone of the World Health Organization (WHO) neonatal 
tetanus elimination program (81), the immunogenicity of TT 
immunization in HIV-infected pregnant women remains largely 
unexplored. In Kenya, titers of TT antibodies at delivery were 
38% lower in HIV-infected as compared with -uninfected women 
(29). However, the proportion of women immunized with TT 
during pregnancy was not reported.
Streptococcus pneumoniae
In Brazil, immunization of HIV-infected pregnant women with a 
pneumococcal polysaccharide vaccine during the third trimester 
of pregnancy was associated with 46–72% antibody transfer ratios 
(36). Moreover, serotype-specific antibody levels waned rapidly 
in HIV-exposed infants over the first 6 months of life with an esti-
mated time to antibody levels <0.35 μg/ml for different serotypes 
(1, 3, 5, 6B, and 9V) ranging between 0.6 and 2.7 months (36). 
This rapid waning of passive immunity could place HIV-exposed 
infants at risk for invasive pneumococcal disease during highly 
vulnerable period of early life.
Group B Streptococcus
The first study on the immunogenicity of a GBS vaccine in HIV-
infected and -uninfected pregnant women was recently conducted 
in Malawi and South Africa (41). Women were immunized with 
a non-adjuvanted GBS capsular polysaccharide (serotypes Ia, Ib, 
and III) between 24 and 35 weeks of gestation. Antibody responses 
were lower in HIV-infected than in -uninfected women. Transfer 
ratios were similar (0.49–0.72) in HIV-infected and -uninfected 
women. At birth, HIV-exposed children had lower antibody titers 
than -unexposed children, and antibody decay was similar in the 
two groups during the first 6 weeks of life.
Reduction of Maternal inflammation  
by ARv Therapy
The impact of ARV therapy on placental inflammation induced 
by maternal HIV infection remains unclear. Historical studies 
indicating an increased expression of inflammatory mediators in 
the placenta of HIV-infected as compared with -uninfected preg-
nant women included patients who were untreated or received 
AZT prophylaxis (63–65). More recent studies reported an 
increased secretion of leukemia inhibiting factor (LIF), TNF-α, 
and IL-8 by placental explants from HIV-infected women under 
mono-, bi-, or tri-ARV therapy as compared with -uninfected 
women (82). However, placental tissues from these HIV-infected 
pregnant women expressed lower levels of mRNA for TNF-α 
and IL-8 as compared with -uninfected women. It was suggested 
that this discrepancy might be related to the fact that cytokine 
secretion by placental explants had been measured ex vivo after 
8Abu-Raya et al. Transfer of Maternal Immunity to HEU Newborns
Frontiers in Immunology | www.frontiersin.org August 2016 | Volume 7 | Article 338
ReFeReNCeS
1. World Health Report. Make Every Mother and Child Count. Geneva: WHO 
(2005).
2. Lawn JE, Cousens S, Zupan J; Lancet Neonatal Survival Steering Team. 4 mil-
lion neonatal deaths: when? where? why? Lancet (2005) 365(9642):891–900. 
doi:10.1016/S0140-6736(05)71048-5 
3. Ghazal P, Dickinson P, Smith CL. Early life response to infection. Curr Opin 
Infect Dis (2013) 26(3):213–8. doi:10.1097/QCO.0b013e32835fb8bf 
4. Kollmann TR, Levy O, Montgomery RR, Goriely S. Innate immune function 
by toll-like receptors: distinct responses in newborns and the elderly. Immunity 
(2012) 37(5):771–83. doi:10.1016/j.immuni.2012.10.014 
5. Niewiesk S. Maternal antibodies: clinical significance, mechanism of inter-
ference with immune responses, and possible vaccination strategies. Front 
Immunol (2014) 5:446. doi:10.3389/fimmu.2014.00446 
6. Turfkruyer M, Verhasselt V. Breast milk and its impact on maturation of 
the neonatal immune system. Curr Opin Infect Dis (2015) 28(3):199–206. 
doi:10.1097/QCO.0000000000000165 
7. Abu Raya B, Srugo I, Kessel A, Peterman M, Bader D, Peri R, et al. The induc-
tion of breast milk pertussis specific antibodies following gestational teta-
nus-diphtheria-acellular pertussis vaccination. Vaccine (2014) 32(43):5632–7. 
doi:10.1016/j.vaccine.2014.08.006 
8. Dauby N, Goetghebuer T, Kollmann TR, Levy J, Marchant A. Uninfected 
but not unaffected: chronic maternal infections during pregnancy, fetal 
immunity, and susceptibility to postnatal infections. Lancet Infect Dis (2012) 
12(4):330–40. doi:10.1016/S1473-3099(11)70341-3 
9. Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol 
(2009) 9(4):235–45. doi:10.1038/nri2524 
10. Moir S, Fauci AS. B-cell exhaustion in HIV infection: the role of immune 
activation. Curr Opin HIV AIDS (2014) 9(5):472–7. doi:10.1097/
COH.0000000000000092 
11. Moir S, Malaspina A, Ho J, Wang W, Dipoto AC, O’Shea MA, et  al. 
Normalization of B cell counts and subpopulations after antiretroviral therapy 
in chronic HIV disease. J Infect Dis (2008) 197(4):572–9. doi:10.1086/526789 
12. Ruffin N, Thang PH, Rethi B, Nilsson A, Chiodi F. The impact of inflammation 
and immune activation on B cell differentiation during HIV-1 infection. Front 
Immunol (2012) 2:90. doi:10.3389/fimmu.2011.00090 
13. Truong HM, Sim MS, Dillon M, Uittenbogaart CH, Dickover R, Plaeger 
SF, et al. Correlation of immune activation during late pregnancy and early 
postpartum with increases in plasma HIV RNA, CD4/CD8 T cells, and serum 
activation markers. Clin Vaccine Immunol (2010) 17(12):2024–8. doi:10.1128/
CVI.00088-10 
14. Slogrove AL, Goetghebuer T, Cotton MF, Singer J, Bettinger JA. Pattern of 
infectious morbidity in HIV-exposed uninfected infants and children. Front 
Immunol (2016) 7:164. doi:10.3389/fimmu.2016.00164 
15. Epalza C, Goetghebuer T, Hainaut M, Prayez F, Barlow P, Dediste A, et al. High 
incidence of invasive group B streptococcal infections in HIV-exposed unin-
fected infants. Pediatrics (2010) 126(3):e631–8. doi:10.1542/peds.2010-0183 
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level of cytokines’ mRNA expression (82). In an in vitro model of 
placental histocultures, it was shown that AZT decreases levels of 
TNF-α mRNA expression in placental microexplants (83).
In a study conducted in Brazil, HIV-infected pregnant women 
under HAART had higher plasma levels of IL-1β and TNF-α and 
lower levels of the anti-inflammatory cytokine IL-10 as compared 
with HIV-infected untreated and -uninfected pregnant women 
(84). Interestingly, the same cytokine profile was observed in 
HAART-exposed newborns. These increased levels of inflam-
matory cytokines were associated with an increased production 
of TNF-α and IFN-γ and a decreased production of IL-10 by T 
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Together, these data suggest complex interactions between 
ARV therapy during pregnancy and inflammatory responses 
in the mother and at the maternofetal interface. Further studies 
are needed to define these interactions in more details and their 
potential clinical consequences.
CONCLUDiNG ReMARKS
There is considerable evidence that HIV infection alters the 
transfer of maternal immune factors to HIV-exposed new-
borns and young infants. A negative impact on the transfer of 
maternal antibodies through the placenta has been observed 
in many settings for many antigen specificities. However, some 
studies reported preserved transfer of antibodies to pathogen 
or vaccine antigens; the reason for these discrepant results is 
unknown. A better understanding of the molecular regulation 
of IgG transfer through the placenta and how it is influenced by 
HIV infection is clearly needed. Further studies to determine 
the clinical consequences of the decreased transfer of maternal 
antibodies are also needed. The fact that the concentration of 
antibodies is preserved in breast milk of HIV-infected women 
supports a compensatory role of breast-feeding in the protection 
of HIV-exposed infants. On the other hand, immune activation 
in HIV-infected pregnant women is associated with produc-
tion of inflammatory cytokines at the maternofetal interface 
and with inflammatory responses in the newborn. The clinical 
consequences of these immune alterations could include prema-
ture delivery, increased susceptibility to severe infections, and 
impaired neurological development. Immune activation may 
also play a role in the decreased transfer of maternal antibodies. 
The two factors may, therefore, interact and impact the health 
of HIV-exposed infants. Maternal immunization offers the 
potential to compensate for the decreased transfer of maternal 
antibodies. However, the impact of maternal HIV infection 
on vaccine responses, on the transfer of maternal antibodies 
through the placenta and breast milk, and on their waning in 
infants is likely to vary according the vaccine used and should be 
evaluated on a case-by-case basis. Finally, data suggest complex 
interactions between ARV prophylaxis during pregnancy and 
inflammatory responses in the mother and at the maternofetal 
interface. More studies are needed to clarify them and their pos-
sible clinical consequences. Despite about 20 years of research, 
the impact of maternal HIV infection on the health of HEU 
children remains poorly understood.
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